SanjivSAgarwalaMD

Oncology • Easton, PA

Chief of medical oncology and hematology at St. Luke

Join to view full profile

Dr. Agarwala is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Agarwala's full profile

Already have an account?

Office
1600 St Lukes Blvd
Easton, PA 18045
Phone+1 610-628-7000

Fax+1 610-628-7001
Is this information wrong?

Education & Training

UPMC Medical EducationResidency, Internal Medicine, 1992 - 1993
UPMC Medical EducationFellowship, Hematology and Medical Oncology, 1990 - 1991
Seth G.S. Medical CollegeClass of 1984

Certifications & Licensure

PA State Medical License 1993 - 2024
WI State Medical License 1993 - 1995
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2013

Clinical Trials

High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma Start of enrollment: 1999 Mar 25
Active, not recruiting
Phase 3
FR901228 in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma Start of enrollment: 2005 Oct 04
Terminated
Phase 2
Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery Start of enrollment: 2007 Jun 01
Active, not recruiting
Phase 3
Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer Start of enrollment: 2006 Sep 15
Completed
Phase 2
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Start of enrollment: 2008 Aug 08
Active, not recruiting
Phase 3
Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer Start of enrollment: 2009 Apr 01
Completed
Phase 3
Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery Start of enrollment: 2009 May 15
Active, not recruiting
Phase 2
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma Start of enrollment: 2009 Nov 17
Active, not recruiting
Phase 3
A Study to Assess PV-10 Chemoablation of Cancer of the Liver Start of enrollment: 2009 Oct 01
Active, not recruiting
Phase 1
Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy Start of enrollment: 2011 Jan 18
Completed
Phase 2
Radiation Therapy With or Without Chemotherapy in Patients With Stage I-IIA Cervical Cancer Who Previously Underwent Surgery Start of enrollment: 2010 Apr 12
Active, not recruiting
Phase 3
Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer Start of enrollment: 2010 Sep 21
Active, not recruiting
Phase 2
Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery Start of enrollment: 2010 Jun 01
Active, not recruiting
Phase 3
Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer Start of enrollment: 2011 May 16
Completed
Not Applicable
Expanded Access Protocol for PV-10 for Cutaneous or Subcutaneous Tumors
No longer available
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
Active, not recruiting
Phase 3
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery Start of enrollment: 2011 May 25
Active, not recruiting
Phase 3
A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer Start of enrollment: 2011 Jun 01
Unknown status
Phase 1, Phase 2
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy Start of enrollment: 2011 Aug 01
Completed
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma Start of enrollment: 2012 Jun 03
Completed
HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma Start of enrollment: 2012 Aug 01
Terminated
Phase 4
Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma Start of enrollment: 2013 Jul 12
Completed
Phase 3
Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Start of enrollment: 2013 Oct 14
Completed
Phase 2
MEK162 for Patients With RAS/RAF/MEK Activated Tumors Start of enrollment: 2013 Oct 10
Completed
Phase 2
Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma Start of enrollment: 2013 Dec 13
Active, not recruiting
Phase 3
A Phase 1 Dose Escalation Study of GC4419 in Combination With Chemoradiation for Squamous Cell Cancer of the Head & Neck Start of enrollment: 2013 Aug 01
Completed
Phase 1
A Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors Start of enrollment: 2017 Jun 09
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

Systemic Therapy for Melanoma: ASCO Guideline Update Q and A.
Vernon K Sondak, Michael B Atkins, Hans Messersmith, Anthony Provenzano, Rahul Seth, Sanjiv S Agarwala> ;JCO Oncology Practice. 2024 Feb 1
12 citations
Systemic Therapy for Melanoma: ASCO Guideline Update.
Rahul Seth, Sanjiv S Agarwala, Hans Messersmith, Krishna C Alluri, Paolo A Ascierto, Michael B Atkins, Kathryn Bollin, Matias Chacon, Nancy Davis, Mark B Faries, Pauli...> ;Journal of Clinical Oncology. 2023 Oct 20
2 citations
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 1st-3rd, 2022-Naples, Italy).
Paolo A Ascierto, Sanjiv S Agarwala, Allison Betof Warner, Marc S Ernstoff, Bernard A Fox, Thomas F Gajewski, Jérôme Galon, Claus Garbe, Brian R Gastman, Jeffrey E Ger...> ;Journal of Translational Medicine. 2023 Jul 28
6 citations
Phase 1 study of the pan-RAF inhibitor tovorafenib in patients with advanced solid tumors followed by dose expansion in patients with metastatic melanoma.
Drew W Rasco, Theresa Medina, Pippa Corrie, Anna C Pavlick, Mark R Middleton, Paul Lorigan, Chris Hebert, Ruth Plummer, James Larkin, Sanjiv S Agarwala, Adil I Daud, J...> ;Cancer Chemotherapy and Pharmacology. 2023 Jul 1
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd - 4th, 2021, Italy).
Ascierto, P., Agarwala, S., Blank, C., Caracò, C., Carvajal, R., Ernstoff, M., Ferrone, S., Fox, B., Gajewski, T., Garbe, C., Grob, J., Hamid, O., Krogsgaard, M., Lo, ...> ;Journal of Translational Medicine. 2022 Sep 4
2 citations
Tilsotolimod Exploits the TLR9 Pathway to Promote Antigen Presentation and Type 1 IFN Signaling in Solid Tumors: A Multicenter International Phase I/II Trial (ILLUMINA...
Hani Babiker, Erkut Borazanci, Vivek Subbiah, Sanjiv Agarwala, Alain Algazi, Jacob Schachter, Michael Lotem, Corinne Maurice-Dror, Daniel Hendler, Shah Rahimian, Hans ...> ;Clinical Cancer Research. 2022 Dec 1
A review of the totality of evidence supporting the development and approval of a pegfilgrastim biosimilar (LA-EP2006).
Sanjiv S Agarwala, Ulrich Nagl, Xinghua Guo, Anne Bellon, Jens Heyn, Miryana Dimova-Dobreva, Yu-Ming Shen, Gregor Schaffar, Martin Humphrey, Nicola Mathieson, Natalia ...> ;Current Medical Research and Opinion. 2022 Jun 1
Evaluation of the reporting quality of clinical practice guidelines on melanoma using the RIGHT checklist.
Yongjie Yang, Yanfang Ma, Jingli Lu, Qiwen Zhang, Kelei Guan, Kefeng Liu, Jian Kang, Shuzhang Du, Shu Tang, Xuehui Liu, Ailing Zhang, Dirk Schadendorf, Sanjiv S Agarwa...> ;Annals of Translational Medicine. 2021 Jul 1
5 citations
Perspectives in melanoma: meeting report from the “Melanoma Bridge” (December 5th–7th, 2019, Naples, Italy)
Paolo A. Ascierto, Igor Puzanov, Sanjiv S. Agarwala, Christian U. Blank, Richard D. Carvajal, Sandra Demaria, Reinhard Dummer, Marc S. Ernstoff, Soldano Ferrone, Berna...> ;Journal of Translational Medicine. 2020 Sep 7
2 citations
The Great Debate at "Melanoma Bridge", Naples, December 7th, 2019.
Paolo A. Ascierto, Sanjiv S. Agarwala, Alexander M.M. Eggermont, Jeffrey E. Gershenwald, Jean-Jacques Grob, Omid Hamid, Olivier Michielin, Michael A. Postow, Igor Puza...> ;Journal of Translational Medicine. 2020 Apr 16
66 citations
Intratumoral delivery of tavokinogene telseplasmid yields systemic immune responses in metastatic melanoma patients.
Alain Algazi, Shailender Bhatia, Sanjiv S. Agarwala, M. Molina, Karl D. Lewis, Mark B. Faries, Lawrence Fong, Lauren P. Levine, M. Franco, Arielle Oglesby, Carmen Ball...> ;Annals of Oncology. 2020 Apr 1
156 citations
Systemic Therapy for Melanoma: ASCO Guideline.
Rahul Seth, Hans Messersmith, Varinder Kaur, John M. Kirkwood, Ragini R. Kudchadkar, Jennifer L. McQuade, Anthony F. Provenzano, Umang Swami, Jeffrey S. Weber, Krishna...> ;Journal of Clinical Oncology. 2020 Mar 31
1455 citations
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048) : a ...
Barbara Burtness, Kevin J. Harrington, Richard Greil, Denis Soulières, Makoto Tahara, Gilberto de Castro, Amanda Psyrri, Neus Baste, Prakash Neupane, Åse Bratland, Tho...> ;Lancet. 2019 Nov 23
52 citations
Phase IIb, Randomized, Double-Blind Trial of GC4419 Versus Placebo to Reduce Severe Oral Mucositis Due to Concurrent Radiotherapy and Cisplatin For Head and Neck Cancer.
Carryn M. Anderson, Christopher M. Lee, Deborah P. Saunders, Amarinthia Curtis, Neal Dunlap, Chaitali Singh Nangia, Arielle S. Lee, Sharon M. Gordon, Philip Kovoor, Ro...> ;Journal of Clinical Oncology. 2019 Oct 16
11 citations
Perspectives in melanoma: meeting report from the Melanoma Bridge (November 29th–1 December 1st, 2018, Naples, Italy)
Paolo A. Ascierto, Sanjiv S. Agarwala, Gerardo Botti, Alfredo Budillon, Michael A. Davies, Reinhard Dummer, Marc S. Ernstoff, Soldano Ferrone, Silvia C. Formenti, Thom...> ;Journal of Translational Medicine. 2019 Jul 22
26 citations
Management of metastatic cutaneous melanoma: updates in clinical practice:
Gustavo Schvartsman, Patricia Taranto, Isabella C. Glitza, Sanjiv S. Agarwala, Michael B. Atkins, Antonio C. Buzaid> ;Therapeutic Advances in Medical Oncology. 2019 May 22
16 citations
Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advanced NRAS - or BRAF -mutated melanoma
Carla M.L. van Herpen, Sanjiv S. Agarwala, Axel Hauschild, Carola Berking, J. Thaddeus Beck, Dirk Schadendorf, Rob L. H. Jansen, Paola Queirolo, Paolo A. Ascierto, Chr...> ;Oncotarget. 2019 Mar 5
34 citations
Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries.
L. Kandolf Sekulovic, Jun Guo, Sanjiv S. Agarwala, Axel Hauschild, Grant A. McArthur, Gabriela Cinat, A. Wainstein, Christian Caglevic, Paul Lorigan, Helen Gogas, M. A...> ;European Journal of Cancer. 2018 Nov 1
15 citations
A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma
Joseph I. Clark, Jatinder Singh, Marc S. Ernstoff, Christopher D. Lao, Lawrence E. Flaherty, Theodore F. Logan, Brendan D. Curti, Sanjiv S. Agarwala, Bret Taback, Lee ...> ;Journal for Immunotherapy of Cancer. 2018 Jul 27
6 citations
Perspectives in melanoma: Meeting report from the Melanoma Bridge (30 November–2 December, 2017, Naples, Italy)
Paolo A. Ascierto, Igor Puzanov, Sanjiv S. Agarwala, Carlo Bifulco, Gerardo Botti, Corrado Caracò, Gennaro Ciliberto, Michael A. Davies, Reinhard Dummer, Soldano Ferro...> ;Journal of Translational Medicine. 2018 Jul 21
51 citations
An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0
Ryan J. Sullivan, Michael B. Atkins, John M. Kirkwood, Sanjiv S. Agarwala, Joseph I. Clark, Marc S. Ernstoff, Leslie A. Fecher, Thomas F. Gajewski, Brian R. Gastman, D...> ;Journal for Immunotherapy of Cancer. 2018 May 30
139 citations
Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
Michele Maio, Karl D. Lewis, Lev V. Demidov, Mario Mandalà, Igor Bondarenko, Paolo A. Ascierto, Christopher Herbert, Andrzej Mackiewicz, Piotr Rutkowski, Alexander Gum...> ;The Lancet. Oncology. 2018 Apr 1
49 citations
Phase 1b/2a Trial of the Superoxide Dismutase Mimetic GC4419 to Reduce Chemoradiotherapy-Induced Oral Mucositis in Patients With Oral Cavity or Oropharyngeal Carcinoma.
Carryn M. Anderson, Stephen T. Sonis, Christopher M. Lee, Douglas Adkins, Bryan G. Allen, Wenqing Sun, Sanjiv S. Agarwala, Madhavi L. Venigalla, Yuhchyau Chen, Weining...> ;International Journal of Radiation Oncology, Biology, Physics. 2018 Feb 1
127 citations
Sentinel Lymph Node Biopsy and Management of Regional Lymph Nodes in Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice...
Sandra L. Wong, Mark B. Faries, Erin B. Kennedy, Sanjiv S. Agarwala, Tim Akhurst, Charlotte E. Ariyan, Charles M. Balch, Barry S. Berman, Alistair J. Cochran, Keith A....> ;Annals of Surgical Oncology. 2018 Feb 1
116 citations
Sentinel Lymph Node Biopsy and Management of Regional Lymph Nodes in Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice...
Sandra L. Wong, Mark B. Faries, Erin B. Kennedy, Sanjiv S. Agarwala, Tim Akhurst, Charlotte E. Ariyan, Charles M. Balch, Barry S. Berman, Alistair J. Cochran, Keith A....> ;Journal of Clinical Oncology. 2017 Dec 12
Join now to see all

Lectures

Efficacy and safety of entinostat (ENT) and pembrolizumab (PEMBRO) in patients with melanoma progressing on or after a PD-1/L1 blocking antibody.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

Press Mentions

Groundbreaking Trial by Indian American Researcher Sanjiv Agarwala Sees Cancerous Tumors ‘Flake Off’July 3rd, 2019
Cancerous Tumors Flake off After Injection of Exotic ‘Rose Bengal’ in Groundbreaking St. Luke’s TrialJune 27th, 2019
Optimizing Adjuvant Strategies Extends RFS in High-Risk MelanomaMarch 11th, 2019
Join now to see all

Grant Support

Ph1 Stdy Epidermal Grwth FCT REC Tyrosine Kinase INH Combo W/DocetaxelNational Center For Research Resources2005
PH II UCN-01 Metastatic MelanomaNational Center For Research Resources2005
PHI Dose Escal. Study Eval Safety Of AlbuleukinNational Center For Research Resources2004
Ph3, Mc, Ol, Surv/Safety Study Of Head/Neck CarcinomaNational Center For Research Resources2004
Ph1 Study EGFR Tyrosine Kinase Inhibitor W/ DocetaxelNational Center For Research Resources2004
A RAND Study Of Four Weeks High Dose IFN 2B In MelanomaNational Center For Research Resources2004
Four Week High Dose Interferon A2B In Stage IIA MelanomaNational Center For Research Resources2000–2002
Phase II Study Of Temozolomide (SCH52365) Prior To Radiation TherapyNational Center For Research Resources1997–2002
Phase I Study Of Recurrent Or Metastatic Squamous Cell Carcinoma Of Head/NeckNational Center For Research Resources1997–2002
Temozolomide In Treatment Of Metastatic Melanoma W/ Brain MetastasesNational Center For Research Resources1999–2000
Recombinant Keratinocyte Growth Factor For Head &Neck CancerNational Center For Research Resources1999–2000
OPEN Label Randomized Study To Eval Effect Safety Of 2 TreatmentsNational Center For Research Resources1999–2000
Phase II Study Of Suramin In Patients With Metastatic MelanomaNational Center For Research Resources1997–2000
Temozolomide Treatment In Metastatic Melanoma With Brain MetastasesNational Center For Research Resources1999
Phase II Study To Evaluate Safety Of Two Treatment Regimes For Head/Neck CancerNational Center For Research Resources1999
Phase I/II Study Of Recombinant Keratinocyte Growth Factor In Head/Neck CancerNational Center For Research Resources1999
Phase I Study Of Temozolomide In Combo With Cisplatin In Advanced Cancer PTSNational Center For Research Resources1998–1999
Phase I Study Of Temozolomide In Combination With Cisplatin In Advanced CancerNational Center For Research Resources1997
Phase II Trial Of Topotecan In Patients With Metastatic Squamous CarcinomaNational Center For Research Resources1996–1997